A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: The BELIEVE study

British Journal of Dermatology

Volumn 163, Issue 2, 2010, Pages 402-411

  Thaci D ^a   Ortonne, J P ^b   Chimenti, S ^c   Ghislain, P D ^d   Arenberger, P ^e   Kragballe, K ^f   Saurat, J H ^g   Khemis, A ^b   Sprogel P ^h   Esslinger, H U ⁱ   Unnebrink, K ⁱ   Kupper, H ⁱ  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UCL Saint Luc   (Belgium)

^e CHARLES UNIVERSITY   (Czech Republic)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h LEO PHARMA A S   (Denmark)

ⁱ ABBOTT GMBH AND CO KG   (Germany)

Author keywords

adalimumab; betamethasone; calcipotriol; combination drug therapy; psoriasis; treatment outcome

Indexed keywords

ADALIMUMAB; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL;

ADULT; ARTICLE; BRONCHOPNEUMONIA; CANDIDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; HEPATITIS; HERPES ZOSTER; HUMAN; INFECTION; LIVER DISEASE; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN CANCER; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; TUBERCULOSIS;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 77954874906     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09791.x     Document Type: Article

References (19)

1. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 23 (Suppl. 2 1 70.
2. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009 60 : 643 659.
3. Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet 2007 370 : 272 284.
4. Nast A, Reytan N, Rosumeck S et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008 22 : 1337 1342.
5. Augustin M, Krüger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008 216 : 366 372.
6. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 61 : 451 485.
7. van Duijnhoven MW, Korver JE, Vissers WH et al. Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. J Eur Acad Dermatol Venereol 2006 20 : 27 33.
8. Campione E, Mazzotta A, Paterno EJ et al. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm Venereol 2009 89 : 288 291.
9. Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994 189 : 260 264.
10. Mason A, Mason J, Cork M et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009 2 : CD005028.
11. Kragballe K, Noerrelund KL, Lui H et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004 150 : 1167 1173.
12. Kragballe K, Austad J, Barnes L et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006 213 : 319 326. (Pubitemid 44837020)
13. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
14. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
15. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
16. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 58 : 826 850. (Pubitemid 351509656)
17. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 161 : 987 1019.
18. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005 19 (Suppl. 3 2 6.
19. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004 140 : 408 414.